Member Info for Hogbog

Ciz is not an AIM share!!

Closed at .62 on II

The patience of some people staggers me……..

Someone just sold a few doe 1.44. Crazy.

The value of this company is now at least five times current mcap the SP will hopefully catch up with newsflow and when we get out of August.

Sizzling soon we hope

Great update at last and great news for health, healthcare and shareholders too.

Absolutely. Best wishes.

TT. : I said “some larger buys coming in”. No one mentioned rolling! If you look through you will see quite a number before and since my post. You seem dedicated to destroying others hope here! Not always a good or credible look. Cheer up!

Is a buy ( not a sell)

Hog bog has 7.3m

Some larger buys starting now in anticipation of news.

Thank you LB. One of the best quality posts ever seen on LSE.

Appreciate it.

My thoughts on this company are: great science and scientists, super special ‘product’, masses of potential, but with a below par board and poor shareholder engagement. They have loyal shareholders who resist boredom, but whose tolerance is finite.

Between this and the payment/non-payment of the July royalty, an RNS is certainly needed unless Allan is trying to save another £250 quid!

Https://www.cizzlebio.com/press-releases/jama-surgery-validates-dex-g2-gastric-cancer-blood-test?ss_source=sscampaigns&ss_campaign_id=68924f3663dd0b172a97e300&ss_email_id=689250b3efc5823027b256c6&ss_campaign_name=Major+Milestone+for+Early+Cancer+Detection&ss_campaign_sent_date=2025-08-05T18%3A43%3A20Z

Sorry to heat that TT best wishes.

Cizzle Bio, Inc.

JAMA Surgery: New Study Confirms the Diagnostic Power of DEX-G2

Cizzle Bio — August 5, 2025

We’re proud to share that our DEX-G2 blood test for early cancer detection has been validated in a clinical study published in JAMA Surgery. The DESTINEX multicenter study showed 95% sensitivity for early-stage gastric cancer and 96.8% diagnostic accuracy, confirming the test’s strength as a minimally invasive, biomarker-based tool.

This is a major milestone for Cizzle Bio and the future of early detection. We are now preparing DEX-G2 for use through CLIA-certified labs to help make earlier diagnosis more accessible to patients and …

Latest study out. Great results great news.

Be there!

The warrants mentioned in the fundraise are above £3.50. This is therefore expected to go well above that. Patience.

Our refiner is funded,

It’s the start of big things